A CBS News investigation published June 8, 2026, has uncovered that physicians in the United States are openly promoting and prescribing retatrutide to patients despite the drug not yet receiving approval from the U.S. Food and Drug Administration. The report, which aired as part of CBS’s ongoing coverage of the weight-loss drug market, raises serious questions about off-label prescribing practices, patient safety, and the regulatory gaps that allow an investigational medication to reach patients outside of clinical trials.
The investigation comes at a pivotal moment for retatrutide, Eli Lilly’s triple-hormone receptor agonist (targeting GLP-1, GIP, and glucagon receptors), which just days earlier presented landmark Phase 3 data at the American Diabetes Association’s 86th Scientific Sessions in Orlando. The TRIUMPH-1 results — showing average weight loss of up to 28.3% — have generated enormous public enthusiasm, but the CBS report reveals that some doctors have already been capitalizing on that enthusiasm well before the data was formally presented.
How Doctors Are Promoting an Unapproved Drug
According to the CBS investigation, physicians have been promoting retatrutide through social media channels, telehealth platforms, and in some cases, direct-to-patient marketing. The drug is being offered through compounding pharmacies — facilities that can legally produce compounded versions of medications but operate under significantly less regulatory oversight than conventional pharmaceutical manufacturers.
Compounded retatrutide is not the same as the Eli Lilly investigational product. It is manufactured by third-party compounding pharmacies using raw peptide ingredients sourced from FDA-registered facilities, but the final compounded product has not undergone the rigorous quality control, sterility testing, or bioequivalence studies required for FDA-approved medications. Patients receiving compounded retatrutide cannot be certain of the purity, potency, or safety of what they are injecting.
The CBS report identified multiple telehealth providers offering retatrutide prescriptions with minimal screening — in some cases, patients reported receiving prescriptions after brief online consultations that did not include comprehensive metabolic panels, cardiac assessments, or screening for contraindications such as a personal or family history of medullary thyroid carcinoma, which is a boxed warning for the entire GLP-1 receptor agonist class.
Safety Concerns
The safety implications are significant. Retatrutide’s triple-agonist mechanism, while responsible for its remarkable efficacy, also carries a distinct side effect profile. Clinical trial data shows that gastrointestinal adverse events — nausea, vomiting, diarrhoea, and constipation — occur at higher rates and with greater severity compared to single- or dual-agonist therapies. The glucagon receptor activation, unique to retatrutide among late-stage obesity drugs, can increase heart rate and affect liver enzyme levels, requiring monitoring that patients obtaining the drug through unregulated channels are unlikely to receive.
Additionally, retatrutide’s profound appetite suppression raises concerns about inadequate nutrition — particularly protein intake, micronutrient deficiencies, and the risk of muscle loss that accompanies rapid weight reduction. In clinical trials, participants received structured dietary counselling and regular monitoring; patients obtaining retatrutide through telehealth compounding prescriptions typically receive no such support.
The CBS investigation also highlighted the absence of long-term safety data for retatrutide. While the TRIUMPH program has demonstrated safety over treatment periods of up to 72 weeks, the drug has not been studied over the multi-year timeframes that would be expected for a medication likely to be used chronically. Patients taking compounded retatrutide outside of a clinical trial are effectively participating in an uncontrolled experiment with no systematic safety monitoring.
Regulatory Context
Retatrutide remains an investigational drug. Eli Lilly has not yet submitted a New Drug Application (NDA) to the FDA, though the company has indicated that regulatory submissions are anticipated following the completion of the TRIUMPH Phase 3 program. Until the FDA completes its review — a process that typically takes 10–12 months for priority review designations — the drug cannot be legally marketed or sold as an approved medication in the United States.
The compounding pharmacy pathway exists in a regulatory grey zone. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can produce medications that are not commercially available, including versions of drugs that are not yet approved, provided they are compounding for individually identified patients with valid prescriptions. The CBS investigation suggests that some telehealth platforms and physicians are exploiting this framework at scale, effectively creating a parallel distribution system for an unapproved drug.
Canadian Context
The CBS investigation carries direct relevance for Canadian patients and healthcare providers. While Canada’s regulatory framework differs from the United States — Health Canada must independently approve retatrutide before it can be legally marketed in Canada — the cross-border flow of health information means that Canadian patients are exposed to the same social media promotion, telehealth advertising, and news coverage that is driving demand in the U.S.
Several specific Canadian concerns emerge from the CBS findings:
Cross-Border Online Pharmacies: Canadian patients may attempt to obtain retatrutide through U.S.-based telehealth platforms or online pharmacies that ship to Canada. Health Canada has repeatedly warned that medications purchased from unregulated international sources may be counterfeit, contaminated, or incorrectly dosed. The CBS investigation amplifies these concerns specifically for retatrutide.
Compounding Pharmacies in Canada: Unlike the United States, Canada’s compounding regulatory framework is provincially administered, creating a patchwork of oversight that varies significantly across jurisdictions. Some Canadian compounding pharmacies may already be producing compounded GLP-1 receptor agonists — and as retatrutide awareness grows, demand for compounded versions in Canada is likely to follow the U.S. pattern.
Provincial Drug Plan Implications: When retatrutide eventually receives Health Canada approval, provincial drug plans will need to assess whether to cover the medication. The CBS investigation underscores the importance of ensuring that access occurs through regulated channels — with appropriate prescribing guidelines, prior authorization criteria, and safety monitoring protocols — rather than through the unregulated compounding market that the U.S. is currently experiencing.
Health Canada’s Vigilance: The Canadian regulator has been monitoring the incretin-based weight loss drug market closely. In 2024–2025, Health Canada issued multiple advisories regarding counterfeit Ozempic and compounded semaglutide. The retatrutide situation mirrors these earlier concerns but is amplified by the drug’s greater potency and more complex safety profile.
What Patients Should Know
For Canadian patients interested in retatrutide, the CBS investigation offers several lessons. First, retatrutide is not currently approved in Canada or the United States. Any source offering the drug for sale is operating outside of established regulatory frameworks. Second, compounded versions of retatrutide have not been evaluated for safety or efficacy by Health Canada, the FDA, or any other major regulatory body. Third, the absence of long-term safety data means that even if the drug appears well-tolerated in the short term, unknown risks may emerge with chronic use.
Patients interested in accessing retatrutide should consult a licensed Canadian physician and consider participation in registered clinical trials if eligible. Health Canada maintains a public database of authorized clinical trials at clinicaltrials.gov, and patients can search for Canadian trial sites recruiting for retatrutide studies. Self-sourcing through unregulated channels carries risks that far outweigh any potential benefit.
Sources
- CBS News, “Doctors caught promoting unregulated weight-loss drug retatrutide, CBS News finds,” June 8, 2026
- CBS News, “Safety concerns over doctors prescribing experimental weight loss drug not approved by FDA,” June 8, 2026
- Eli Lilly and Company, TRIUMPH-1 Phase 3 Clinical Trial Results, ADA 86th Scientific Sessions, June 2026
- Health Canada, “Buying drugs online: What you need to know,” 2025
- U.S. Food and Drug Administration, Section 503A of the Federal Food, Drug, and Cosmetic Act — Compounding